Grand River Aseptic Manufacturing Completes Phase II of Facility Expansion

Grand River Aseptic Manufacturing has completed phase II of its facility expansion with the installation of two new sterile filling lines.

Grand River Aseptic Manufacturing (GRAM), a parenteral drug product contract development and manufacturing organization (CDMO), announced the completion of Phase II of its facility expansion on Aug. 17, 2022.

The expansion includes the installation of GRAM’s two new sterile Bausch+Ströbel filling lines. One is a modular vial and syringe/cartridge fill line with SKAN isolator, and the other is a high-speed vial fill line with SKAN isolator. According to a company press release, they are identical in technology to the company’s previously installed fill line with IMA lyophilizer, which began manufacturing product in September 2020. GRAM’s filling capacity now reaches over 50 million units per year.

GRAM’s aseptic filling facility is designed with independent formulation and filling suites. In addition to completing Phase II, GRAM has significantly progressed Phase III of their facility expansion, which will offer more filling and finishing capacity.

“GRAM has assembled a team of experts within our company to serve new and existing partners on industry-leading equipment that elevates the breadth of what a CDMO can provide,” said Tom Ross, president and CEO of Grand River Aseptic Manufacturing, in the press release. “Continuity of technology across all our fill lines benefits our clients as their products transition from the clinic to the market. The capabilities established at GRAM with new facilities and equipment will better serve our clients focused on high-value biologic drug products. We are excited and ready to offer top-of-the-line solutions to the marketplace and entertain even more guests here in Grand Rapids.”

Source: GRAM